SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on February 6, 2003; DOI 10.1182/blood-2002-10-3297. This Article Full Text Full Text (PDF) All Versions of this Article: 2002-10-3297v1 101/12/5007    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Herling, M. Articles by Jones, D. Search for Related Content PubMed PubMed Citation Articles by Herling, M. Articles by Jones, D. Related Collections Immunobiology Neoplasia Oncogenes and Tumor Suppressors Brief Reports Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 15 June 2003, Vol. 101, No. 12, pp. 5007-5009 NEOPLASIA Brief report TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+ CD56+ blastic tumors of skin Marco Herling, Michael A. Teitell, Rhine R. Shen, L. Jeffrey Medeiros, and Dan Jones From the Department of Hematopathology, the University of Texas MD Anderson Cancer Center, Houston, TX; and the Department of Pathology and Laboratory Medicine, UCLA School of Medicine, Los Angeles, CA. Initially considered to be of natural killer (NK)–cell origin, CD4+ CD56+ blastic tumors (BTs) of skin have recently been proposed to be of dendritic cell lineage. We have previously described BTs with transformation to myelomonocytic leukemia. Here we report expression of the lymphoid proto-oncogene TCL1 in 10 (83%) of 12 BTs and in lymph node plasmacytoid dendritic cells (DC2s). TCL1 was also expressed in myelomonocytic blasts of 3 transformed BT cases but not in true NK-cell tumors (n = 18), de novo acute myelomonocytic leukemias (1 of 14, 7%), or mature T-cell malignancies (1 of 112, < 1%), with the exception of T-prolymphocytic leukemia (T-PLL). All BT cases were also positive for the DC2-associated marker CD123. These results further support derivation of BTs from DC2s, and demonstrate that TCL1 expression in this tumor is common to the immature blastoid, lymphoid-appearing, and subsequent myelomonocytic phases of this disease. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: M. Herling, K. A. Patel, N. Weit, N. Lilienthal, M. Hallek, M. J. Keating, and D. Jones High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia Blood, November 19, 2009; 114(21): 4675 - 4686. [Abstract] [Full Text] [PDF] D. M. P. Cronin, T. I. George, and U. N. Sundram An Updated Approach to the Diagnosis of Myeloid Leukemia Cutis Am J Clin Pathol, July 1, 2009; 132(1): 101 - 110. [Abstract] [Full Text] [PDF] T. Marafioti, J. C. Paterson, E. Ballabio, K. K. Reichard, S. Tedoldi, K. Hollowood, M. Dictor, M.-L. Hansmann, S. A. Pileri, M. J. Dyer, et al. Novel markers of normal and neoplastic human plasmacytoid dendritic cells Blood, April 1, 2008; 111(7): 3778 - 3792. [Abstract] [Full Text] [PDF] M. Herling, K. A. Patel, M. A. Teitell, M. Konopleva, F. Ravandi, R. Kobayashi, and D. Jones High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia Blood, January 1, 2008; 111(1): 328 - 337. [Abstract] [Full Text] [PDF] G. Despouy, M. Joiner, E. Le Toriellec, R. Weil, and M. H. Stern The TCL1 oncoprotein inhibits activation-induced cell death by impairing PKC{theta} and ERK pathways Blood, December 15, 2007; 110(13): 4406 - 4416. [Abstract] [Full Text] [PDF] K. K. Hoyer, M. Herling, K. Bagrintseva, D. W. Dawson, S. W. French, M. Renard, J. G. Weinger, D. Jones, and M. A. Teitell T Cell Leukemia-1 Modulates TCR Signal Strength and IFN-{gamma} Levels through Phosphatidylinositol 3-Kinase and Protein Kinase C Pathway Activation J. Immunol., July 15, 2005; 175(2): 864 - 873. [Abstract] [Full Text] [PDF] R. Willemze, E. S. Jaffe, G. Burg, L. Cerroni, E. Berti, S. H. Swerdlow, E. Ralfkiaer, S. Chimenti, J. L. Diaz-Perez, L. M. Duncan, et al. WHO-EORTC classification for cutaneous lymphomas Blood, May 15, 2005; 105(10): 3768 - 3785. [Abstract] [Full Text] [PDF] F. Garnache-Ottou, L. Chaperot, S. Biichle, C. Ferrand, J.-P. Remy-Martin, E. Deconinck, P. D. de Tailly, B. Bulabois, J. Poulet, E. Kuhlein, et al. Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells Blood, February 1, 2005; 105(3): 1256 - 1264. [Abstract] [Full Text] [PDF] M. Herling, J. D. Khoury, L. T. Washington, M. Duvic, M. J. Keating, and D. Jones A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories Blood, July 15, 2004; 104(2): 328 - 335. [Abstract] [Full Text] [PDF] M. W. Bekkenk, P. M. Jansen, C. J. L. M. Meijer, and R. Willemze CD56+ hematological neoplasms presenting in the skin: a retrospective analysis of 23 new cases and 130 cases from the literature Ann. Onc., July 1, 2004; 15(7): 1097 - 1108. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020